These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
139 related articles for article (PubMed ID: 6430257)
1. l-Deprenyl in atypical depressives. Quitkin FM; Liebowitz MR; Stewart JW; McGrath PJ; Harrison W; Rabkin JG; Markowitz J; Davies SO Arch Gen Psychiatry; 1984 Aug; 41(8):777-81. PubMed ID: 6430257 [TBL] [Abstract][Full Text] [Related]
2. A controlled study of the antidepressant efficacy and side effects of (-)-deprenyl. A selective monoamine oxidase inhibitor. Mann JJ; Aarons SF; Wilner PJ; Keilp JG; Sweeney JA; Pearlstein T; Frances AJ; Kocsis JH; Brown RP Arch Gen Psychiatry; 1989 Jan; 46(1):45-50. PubMed ID: 2491941 [TBL] [Abstract][Full Text] [Related]
3. Biochemical effects of L-deprenyl in atypical depressives. Liebowitz MR; Karoum F; Quitkin FM; Davies SO; Schwartz D; Levitt M; Linnoila M Biol Psychiatry; 1985 May; 20(5):558-65. PubMed ID: 3921065 [TBL] [Abstract][Full Text] [Related]
4. L-deprenyl in Alzheimer's disease. Preliminary evidence for behavioral change with monoamine oxidase B inhibition. Tariot PN; Cohen RM; Sunderland T; Newhouse PA; Yount D; Mellow AM; Weingartner H; Mueller EA; Murphy DL Arch Gen Psychiatry; 1987 May; 44(5):427-33. PubMed ID: 3107514 [TBL] [Abstract][Full Text] [Related]
5. A placebo-controlled trial of L-deprenyl in atypical depression. McGrath PJ; Stewart JW; Harrison W; Wager S; Nunes EN; Quitkin FM Psychopharmacol Bull; 1989; 25(1):63-7. PubMed ID: 2505303 [No Abstract] [Full Text] [Related]
6. Response to phenelzine and imipramine in placebo nonresponders with atypical depression. A new application of the crossover design. Quitkin FM; Harrison W; Stewart JW; McGrath PJ; Tricamo E; Ocepek-Welikson K; Rabkin JG; Wager SG; Nunes E; Klein DF Arch Gen Psychiatry; 1991 Apr; 48(4):319-23. PubMed ID: 2009033 [TBL] [Abstract][Full Text] [Related]
7. Phenelzine v imipramine in atypical depression. A preliminary report. Liebowitz MR; Quitkin FM; Stewart JW; McGrath PJ; Harrison W; Rabkin J; Tricamo E; Markowitz JS; Klein DF Arch Gen Psychiatry; 1984 Jul; 41(7):669-77. PubMed ID: 6375621 [TBL] [Abstract][Full Text] [Related]
9. Treatment of atypical depression with cognitive therapy or phenelzine: a double-blind, placebo-controlled trial. Jarrett RB; Schaffer M; McIntire D; Witt-Browder A; Kraft D; Risser RC Arch Gen Psychiatry; 1999 May; 56(5):431-7. PubMed ID: 10232298 [TBL] [Abstract][Full Text] [Related]
10. Two weeks of treatment with deprenyl (selegiline) does not prolong L-dopa effect in parkinsonian patients: a double-blind cross-over placebo-controlled trial. Rascol O; Montastruc JL; Senard JM; Demonet JF; Simonetta M; Rascol A Neurology; 1988 Sep; 38(9):1387-91. PubMed ID: 3137488 [TBL] [Abstract][Full Text] [Related]
11. A double-blind, placebo-controlled trial of the safety and efficacy of selegiline transdermal system without dietary restrictions in patients with major depressive disorder. Amsterdam JD J Clin Psychiatry; 2003 Feb; 64(2):208-14. PubMed ID: 12633131 [TBL] [Abstract][Full Text] [Related]
12. Antidepressant specificity in atypical depression. Liebowitz MR; Quitkin FM; Stewart JW; McGrath PJ; Harrison WM; Markowitz JS; Rabkin JG; Tricamo E; Goetz DM; Klein DF Arch Gen Psychiatry; 1988 Feb; 45(2):129-37. PubMed ID: 3276282 [TBL] [Abstract][Full Text] [Related]
13. The relative efficacy of l-deprenyl, a selective monoamine oxidase type B inhibitor, in endogenous and nonendogenous depression. Mann JJ; Frances A; Kaplan RD; Kocsis J; Peselow ED; Gershon S J Clin Psychopharmacol; 1982 Feb; 2(1):54-7. PubMed ID: 6802883 [No Abstract] [Full Text] [Related]
14. Columbia atypical depression. A subgroup of depressives with better response to MAOI than to tricyclic antidepressants or placebo. Quitkin FM; Stewart JW; McGrath PJ; Tricamo E; Rabkin JG; Ocepek-Welikson K; Nunes E; Harrison W; Klein DF Br J Psychiatry Suppl; 1993 Sep; (21):30-4. PubMed ID: 8217065 [TBL] [Abstract][Full Text] [Related]
15. Phenelzine and imipramine in mood reactive depressives. Further delineation of the syndrome of atypical depression. Quitkin FM; McGrath PJ; Stewart JW; Harrison W; Wager SG; Nunes E; Rabkin JG; Tricamo E; Markowitz J; Klein DF Arch Gen Psychiatry; 1989 Sep; 46(9):787-93. PubMed ID: 2673130 [TBL] [Abstract][Full Text] [Related]
16. Clinical efficacy of deprenyl, a specific inhibitor of MAOB. Psychopharmacol Bull; 1983; 19(3):328-42. PubMed ID: 6314420 [No Abstract] [Full Text] [Related]
17. L-deprenyl plus L-phenylalanine in the treatment of depression. Birkmayer W; Riederer P; Linauer W; Knoll J J Neural Transm; 1984; 59(1):81-7. PubMed ID: 6425455 [TBL] [Abstract][Full Text] [Related]
18. Deprenyl in Parkinson disease. Eisler T; Teräväinen H; Nelson R; Krebs H; Weise V; Lake CR; Ebert MH; Whetzel N; Murphy DL; Kopin IJ; Calne DB Neurology; 1981 Jan; 31(1):19-23. PubMed ID: 6161320 [TBL] [Abstract][Full Text] [Related]
19. Phenelzine versus imipramine in the treatment of probable atypical depression: defining syndrome boundaries of selective MAOI responders. Quitkin FM; Stewart JW; McGrath PJ; Liebowitz MR; Harrison WM; Tricamo E; Klein DF; Rabkin JG; Markowitz JS; Wager SG Am J Psychiatry; 1988 Mar; 145(3):306-11. PubMed ID: 3278631 [TBL] [Abstract][Full Text] [Related]
20. Response to phenelzine and amitriptyline in subtypes of outpatient depression. Paykel ES; Rowan PR; Parker RR; Bhat AV Arch Gen Psychiatry; 1982 Sep; 39(9):1041-9. PubMed ID: 7052009 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]